Recession-Resistant International Beverage Firm Added to Best Dividend Stocks List

Unlock this Best Dividend Stock Today! Trouble viewing this? View Email as Webpage Recession-Resistant International Beverage Firm Added to Best Dividend Stocks List Dividend.com has added an international beverage firm to the Best Dividend Stocks List and removed a retailer from the list. With the market starting to get a bit dicey, investors are once again making a flight to safety. Consumer products, utility and even healthcare stocks are once again on the menu. The only problem is, many of these safe stocks don’t exactly come with a ton of growth behind them. Luckily, for our new consumer products Best Dividend Stocks List pick, investors can get the best of both worlds – recession-resistant safety and a big amount of growth. Our pick was created as the result of a mega-merger uniting three of the largest beverage companies across the world. With operations in more than 13 countries and sales located in countless more, our pick manages to provide drinks for more than 300 million customers. The best part is that demand for our pick’s products doesn’t seem to be affected by recessionary pressures. Low price points make them accessible to all. But there is also plenty of growth ahead. With only it being year two of the merger, our pick continues to wring out additional cost efficiencies with success. Additionally, our pick has continued to make the move into healthier beverages here in Western Europe and the United States to take advantage of changing health trends. At the same time, rising emerging market growth has allowed it to continue to gain overall sales. All of this has made the firm a dividend champion in its few short years on the planet churning out steady payouts to investors. To summarize, here are five reasons why you should own this stock: Generated more than €11 billion in revenue and more than €2 billion in profits last year. Truly benefiting from M&A, realizing nearly $275 million in synergies in just two years and more is on the way. Recession-resistant product that generates plenty of cash flows and dividends for its shareholders. Pre-merger, its main operating body had 9 years’ worth of dividend growth, and post-merger, the firm has continued to deliver strong payouts to its investors. Healthy payout ratio of 42% and growing yield of 2.52%. Stock Symbol  Unlock   Company Name  Unlock DARS Rating 5.0   Current Yield 2.84% Ex-Div Date  Unlock   Pay Date  Unlock All data in the table above updated as of 10/30/2018. UPGRADE TO UNLOCK THIS STOCK!   MORE ABOUT THIS STOCK Trailing 5-Year Dividend Payout History Annualized Growth Over The Last 5 Years: 10.5%. As a dividend investor, you need access to the best and safest stocks on the market. Dividend.com’s DARS ratings have been providing you with reliable and profitable stock analysis since 2008, and this addition is no exception. UPGRADE TO UNLOCK THIS STOCK!

Our mailing address is: Dividend.com P.O. Box 822 New York, NY 10108 USA Update Subscription Options | Unsubscribe From This List | Forward to a Friend ©2018 Dividend.com. All rights reserved. You are receiving this mailing because you opted-in at our website, Dividend.com, which is in full compliance of the CAN-SPAM Act of 2008.

Free Newsletter

Your daily guide to the latest dividend stock news... Trouble viewing this? View Email as Webpage The Dividend.com Daily Dispatch Today's Top Stories on Dividend.com Citigroup Inc. Leads 155 Securities Going Ex-Dividend This Week Market Wrap for October 26: The Wall of Worry Starts to Grow Most Popular Articles on Dividend.com The Midterms Matter for the Markets   Solid Dividend Growth Earns Biotech Giant Spot on the Best Dividend Stocks List   Understanding the Global Industry Classification System (GICS) Thank You for Subscribing! We hope you've enjoyed this issue of the Dividend.com Daily Dispatch. Make sure you also Upgrade for a Full Year of Dividend.com Premium. We know it will be profitable for you. Best Regards, Dividend.com Connect with Dividend.com Facebook Twitter Email Our mailing address is: Dividend.com P.O. Box 822 New York, NY 10108 USA Update Subscription Options | Unsubscribe From This List | Forward to a Friend ©2018 Dividend.com. All rights reserved. You are receiving this mailing because you opted-in at our website, Dividend.com, which is in full compliance of the CAN-SPAM Act of 2008.

Solid Dividend Growth Earns Biotech Giant Spot on the Best Dividend Stocks List

Unlock this Best Dividend Stock Today! Trouble viewing this? View Email as Webpage Solid Dividend Growth Earns Biotech Giant Spot on the Best Dividend Stocks List Dividend.com has added an international healthcare stocks to the Best Dividend Stocks List and removed an energy producer from the list. Healthcare remains one of the most dynamic sectors around. With a growing and aging population, demand for healthcare solutions and therapies continues to grow. Perhaps the most exciting of these could be the various biotech names. Thanks to long-term trends and a hefty dose of innovation, revenues and profits for various biotech stocks remain robust. The problem is, many biotech stocks live up to their reputation as “lotto tickets.” Most drugs fail to get an approval from regulatory bodies. So, finding a biotech stock that has multiple approvals, generates billions in revenues and pays a growing dividend is rarer than diseases these firms aim to treat. Luckily for our new Best Dividend Stocks List pick, it has all three spades. As one of biotech’s elder statesmen, our new pick has been generating profits and cash flows from its portfolio of blockbuster drugs for decades. Moreover, our new pick has been sharing the love with investors in a big way and thanks to the repatriation tax benefit it’s handing even more cash back to investors through dividends/buybacks. But in healthcare, you’re only as good as your pipeline. Here, again, our pick has plenty of opportunity for future growth. This includes new cancer therapies, cardiovascular drugs and inflammatory diseases. And let’s not forget that its robust cash flows/balances allow it to do some hefty M&A. All in all, our new healthcare pick could be the best blend of growth and stability around. To summarize, here are five reasons why you should own this stock: Blockbuster portfolio of biotech drugs generated revenues of more than $10 billion in the first half of 2018 alone. Since the firm started paying a dividend in 2011, our pick has grown its payout by over 300%. Replacing its aging pipeline with new drugs as well as launching a portfolio of biosimilars on its existing blockbusters to limit lost revenues. Big winner from the Republican tax plan and repatriation holiday – with nearly $30 billion in cash and short-term investments on its balance sheet as of June 30, 2018. Healthy payout ratio of 38% and growing yield of 2.62%. Stock Symbol  Unlock   Company Name  Unlock DARS Rating 5.0   Current Yield 2.70% Ex-Div Date  Unlock   Pay Date  Unlock All data in the table above updated as of 09/25/2018. UPGRADE TO UNLOCK THIS STOCK!   MORE ABOUT THIS STOCK Trailing 5-Year Dividend Payout History Annualized Growth Over The Last 5 Years: 26.1%. As a dividend investor, you need access to the best and safest stocks on the market. Dividend.com’s DARS ratings have been providing you with reliable and profitable stock analysis since 2008, and this addition is no exception. UPGRADE TO UNLOCK THIS STOCK!

Our mailing address is: Dividend.com P.O. Box 822 New York, NY 10108 USA Update Subscription Options | Unsubscribe From This List | Forward to a Friend ©2018 Dividend.com. All rights reserved. You are receiving this mailing because you opted-in at our website, Dividend.com, which is in full compliance of the CAN-SPAM Act of 2008.